HERCULES, Calif. -- October 30, 2018 -- A recent study published online in the Journal of Molecular Diagnostics demonstrated that Droplet Digital PCR (ddPCR) technology can be used to detect mutations in a region of our DNA that is linked to many cancer types, paving the way for the development of new cancer diagnostics and therapies.
Two mutations in the promoter region of the TERT gene, where gene expression is initiated, are highly prevalent throughout many cancer types. The mutations range in frequency from 10 to 70 percent in melanoma, glioblastoma, and thyroid and liver cancers among others, and could serve as potential biomarkers in diagnosing and monitoring patients.
"We wanted to develop ddPCR assays for these TERT promoter mutations since they are very frequently mutated in melanomas, including the one third of melanoma patients who are lacking BRAF and NRAS mutations," said Dr. David Polsky, MD, PhD, a professor of dermatologic oncology at NYU Langone and a senior investigator on this study. "We hope that multiple groups can use these assays in various cancer types and that detecting and quantifying these TERT promoter mutations will be useful in the evaluation and management of cancer patients."
Next-generation sequencing (NGS) technology has commonly been used to detect disease biomarkers. However, NGS has not proven to be successful at accurately detecting TERT promoter mutations because complexities in the DNA sequence in and around the TERT promoter make amplification by PCR extremely difficult. This limits the read depth of NGS and reduces its sensitivity in detecting mutations. While other detection methods such as quantitative PCR (qPCR) exist, they are not sensitive or precise enough for clinical applications such as monitoring cell-free DNA in plasma.
To overcome these challenges, Dr. Polsky and his colleagues at NYU Langone Medical Center and its Perlmutter Cancer Center and scientists at Bio-Rad's Digital Biology Group used ddPCR technology, which can reliably detect and quantify rare mutations with high sensitivity (<0.1 percent) independent of a reference standard.
The researchers developed two ddPCR-based assays to specifically detect the TERT C228T and C250T mutations in clinical samples. The limits of detection for the two assays were 0.062 and 0.051 percent.
In addition, the researchers evaluated the clinical application of the ddPCR assays by testing them in both formalin-fixed paraffin-embedded (FFPE) tissues and plasma samples from patients with metastatic melanoma. They found that the assays detected the mutation in 78 percent of samples and yielded no false positives. The test was able to detect mutation frequencies as low as 0.06 percent, demonstrating its high sensitivity.
"We have found the ddPCR workflow to be quite simple, and we estimate that the cost of the assays would be amenable to patient monitoring, where it would need to be repeated periodically as part of medical care," said Dr. Polsky.
Bio-Rad, Droplet Digital PCR, and ddPCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1 billion in 2017. For more information, please visit http://www.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce new products and the opportunities that may result from such new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "offers," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.